In a controlled clinical trial, patients with a single demyelinating event treated with Betaferon
had a 47% reduction in risk of developing multiple sclerosis compared with those receiving placebo. In a two-year period, clinically definite multiple sclerosis occurred in 45% of the placebo group compared with 28% of the Betaferon group.
Furthermore, Betaferon delayed the time to clinically definite multiple sclerosis by 363 days, from 255 days in the placebo group to 618 days in the Betaferon group.Further information:
Schering Health Care Ltd, The Brow, Burgess Hill, West Sussex RH15 9NE. Tel:
0845 609 6767.